Table 4_Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.docx
Introduction<p>While the APOLLO trial confirmed the clinical efficacy of first-line anlotinib plus penpulimab in unresectable hepatocellular carcinoma (HCC), its economic impact on China’s healthcare system remains underexplored. This study was conducted to evaluate the cost-effectiveness of t...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|